Primary lymph-node staging with 68Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens

Briganti, 2009, Pelvic lymph node dissection in prostate cancer, Eur Urol, 55, 1251, 10.1016/j.eururo.2009.03.012 Joniau, 2013, Mapping of pelvic lymph node metastases in prostate cancer, Eur Urol, 63, 450, 10.1016/j.eururo.2012.06.057 Mattei, 2008, The template of the primary lymphatic landing sites of the prostate should be revisited: results of a multimodality mapping study, Eur Urol, 53, 118, 10.1016/j.eururo.2007.07.035 Wit, 2017, Sentinel node procedure in prostate cancer: a systematic review to assess diagnostic accuracy, Eur Urol, 71, 596, 10.1016/j.eururo.2016.09.007 Hövels, 2008, The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis, Clin Radiol, 63, 387, 10.1016/j.crad.2007.05.022 Udovicich, 2017, 68Ga-prostate-specific membrane antigen-positron emission tomography/computed tomography in advanced prostate cancer: Current state and future trends, Prostate Int, 5, 125, 10.1016/j.prnil.2017.02.003 Perera, 2020, Eur Urol, 77, 403, 10.1016/j.eururo.2019.01.049 Budaeus, 2016, Initial experience of Ga-68-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy, Eur Urol, 69, 393, 10.1016/j.eururo.2015.06.010 Demirkol, 2015, Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process, Prostate, 75, 748, 10.1002/pros.22956 Dewes, 2016, Integration of Ga-68-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study, Radiat Oncol, 11, 73, 10.1186/s13014-016-0646-2 Gupta, 2017, A comparative study of 68Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience, World J Nucl Med, 16, 186, 10.4103/1450-1147.207272 Gupta, 2017, Prostate-specific membrane antigen positron emission tomography-computed tomography for prostate cancer: distribution of disease and implications for radiation therapy planning, Int J Radiat Oncol Biol Phys, 99, 701, 10.1016/j.ijrobp.2017.06.2448 Maurer, 2015, Preoperative lymph node staging in intermediate to highrisk prostate cancer patients using 68Ga-HBED-PSMA PET hybrid imaging—a patient- and field-based analysis, J Urol, 193, E707, 10.1016/j.juro.2015.02.2118 Obek, 2017, The accuracy of Ga-68-PSMA PET/CT in primary lymph node staging in high-risk prostate cancer, Eur J Nucl Med Mol Imaging, 44, 1806, 10.1007/s00259-017-3752-y Roach, 2018, The impact of Ga-68-PSMA PET/CT on management intent in prostate cancer: results of an Australian prospective multicenter study, J Nucl Med, 59, 82, 10.2967/jnumed.117.197160 Sahlmann, 2016, Biphasic Ga-68-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma, Eur J Nucl Med Mol Imaging, 43, 898, 10.1007/s00259-015-3251-y Schwenck, 2017, Comparison of Ga-68-labelled PSMA-11 and C-11-choline in the detection of prostate cancer metastases by PET/CT, Eur J Nucl Med Mol Imaging, 44, 92, 10.1007/s00259-016-3490-6 Sterzing, 2016, Ga-68-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients, Eur J Nucl Med Mol Imaging, 43, 34, 10.1007/s00259-015-3188-1 van Leeuwen, 2017, Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer, BJU Int, 119, 209, 10.1111/bju.13540 Zhang, 2017, Comparison of Ga-68-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer, J Transl Med, 15, 230, 10.1186/s12967-017-1333-2 Esen, 2020, Can Ga-68 PSMA PET/CT replace conventional imaging modalities for primary lymph node and bone staging of prostate cancer?, Eur Urol Focus, 6, 218, 10.1016/j.euf.2019.05.005 Mottet, 2017, EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, 71, 618, 10.1016/j.eururo.2016.08.003 Umbehr, 2013, The role of 11C-choline and 18F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis, Eur Urol, 64, 106, 10.1016/j.eururo.2013.04.019 Maurer, 2016, Current use of PSMA-PET in prostate cancer management, Nat Rev Urol, 13, 226, 10.1038/nrurol.2016.26 Corfield, 2018, 68Ga-prostate specific membrane antigen (PSMA) positron emission tomography (PET) for primary staging of high-risk prostate cancer: a systematic review, World J Urol, 36, 519, 10.1007/s00345-018-2182-1 Hofman, 2020, Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study, Lancet, 395, 1208, 10.1016/S0140-6736(20)30314-7 Yaxley, 2019, Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with 68Ga-PSMA positron emission tomography/computerized tomography compared to histological correlation of pelvic lymph node pathology, J Urol, 201, 815, 10.1097/JU.0000000000000053 Kim, 2019, Urol Int, 102, 27, 10.1159/000493169 Eiber, 2016, Simultaneous 68Ga-PSMA HBED-CC PET/MRI improves the localization of primary prostate cancer, Eur Urol, 70, 829, 10.1016/j.eururo.2015.12.053